Trial Profile
Natalizumab for Multiple Sclerosis in Clinical Practice in Germany - TYSTART
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms TYSTART
- Sponsors Biogen
- 16 Sep 2015 New trial record